Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers.
Tiziana Life Sci PLC (TILS.L) Significant Immunomodulation effects on Biomarkers
Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers.
Tiziana Life Sci PLC (TILS.L) Trial Initiation in a SPMS Patient with Foralumab
Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual
Tiziana Life Sci PLC (TILS.L) Director/PDMR Dealing
PDMR Dealing
Tiziana Life Sci PLC (TILS.Nasdaq.L) Director/PDMR Dealing
London, New York, 21 May 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation
Tiziana Life Sci PLC (TILS.L) Final Results for the Year Ended 31 December 2020
London / New York 18 May 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), (the “Company” or “Tiziana”), a biotechnology company focused on innovative therapeutics for oncology,
Tiziana Life Sci PLC (TILS.L) TLSA interview on Bloomberg TV on 8th May 2021
Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
Tiziana Life Sci PLC (TILS.L) B. Riley Virtual Neuroscience Investor Conference
Tiziana Life Sciences to participate in a Fireside Chat on 28 April 2021 at 10:30 a.m. EDT
Tiziana Life Sci PLC (TILS.L) Announces Plans to List Accustem Sciences Limited in the U.S.
NEW YORK and LONDON, April 13, 2021 – Tiziana Life Sciences plc (NASDAQ: TLSA; LSE: TILS), today announced that its former subsidiary, Accustem Sciences Limited (“Accustem”), intends to file a
Tiziana Life Sci PLC (TILS.L) P2 Study in Moderate to Severe Covid-19 Patients
Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
Tiziana Life Sciences plc (TILS.L) Chairman of Tiziana to give interview on Bloomberg
Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give an interview on Bloomberg Television US at 1:20 PM ET Today